Back to Search Start Over

Structural studies of Mycobacterium tuberculosis DprE1 interacting with its inhibitors.

Authors :
Piton J
Foo CS
Cole ST
Source :
Drug discovery today [Drug Discov Today] 2017 Mar; Vol. 22 (3), pp. 526-533. Date of Electronic Publication: 2016 Sep 22.
Publication Year :
2017

Abstract

The flavoenzyme DprE1 catalyses a crucial step in arabinan production for cell wall biosynthesis in Mycobacterium tuberculosis and is a highly vulnerable drug target. It was first discovered using benzothiazinones (BTZ): exquisitely potent bactericidal agents that are being developed as drugs to treat tuberculosis. Subsequently, many compounds with diverse scaffolds were found to act as either covalent or noncovalent DprE1 inhibitors. Covalent inhibitors, like the BTZ, are all nitroaromatic compounds that serve as suicide substrates after DprE1-mediated nitroreduction. Here, we describe how high-resolution structures of DprE1, alone and in complex with various ligands, explain enzyme activity and inhibition.<br /> (Copyright © 2016 Elsevier Ltd. All rights reserved.)

Details

Language :
English
ISSN :
1878-5832
Volume :
22
Issue :
3
Database :
MEDLINE
Journal :
Drug discovery today
Publication Type :
Academic Journal
Accession number :
27666194
Full Text :
https://doi.org/10.1016/j.drudis.2016.09.014